^
Association details:
| Biomarker: | FGFR4 mutation |
|---|---|
| Cancer: | Gastric Cancer |
| Drug: | Balversa (erdafitinib) (FGFR inhibitor, FGFR1 inhibitor, FGFR4 inhibitor, FGFR2 inhibitor, FGFR3 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor
Published date:
03/24/2017
Excerpt:
In xenografts from human tumor cell lines or patient-derived tumor tissue with activating FGFR alterations, JNJ-42756493 administration results in potent and dose-dependent antitumor activity accompanied by pharmacodynamic modulation of phospho-FGFR and phospho-ERK in tumors.
DOI:
10.1158/1535-7163.MCT-16-0589
